Summary
Menin inhibitors are an emerging class of targeted therapies that transform treatment for genetically defined acute leukemias, particularly KMT2A‑rearranged and NPM1‑mutated AML.
REVUFORJ (revumenib, Syndax) is the first FDA‑approved selective menin inhibitor for relapsed/refractory acute leukemia with KMT2A translocation.
KOMZIFTI (ziftomenib, Kura/Kyowa Kirin) received FDA approval in November 2025 for adults with relapsed/refractory NPM1‑mutated AML with no satisfactory alternatives.
Additional menin inhibitors, such as Johnson & Johnson’s bleximenib, Sumitomo’s enzomenib (DSP‑5336), Servier’s S243249, and further studies of ziftomenib, are...
